Seres Therapeutics Inc [MCRB] Revenue clocked in at $127.24 million, down -18.57% YTD: What’s Next?

Seres Therapeutics Inc [NASDAQ: MCRB] price surged by 6.54 percent to reach at $0.07. The company report on February 27, 2024 at 7:00 AM that Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

The one-year MCRB stock forecast points to a potential upside of 87.36. The average equity rating for MCRB stock is currently 1.86, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Seres Therapeutics Inc [MCRB]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $9.02 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 26, 2023. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on April 21, 2023, representing the official price target for Seres Therapeutics Inc stock. Previously, the target price had yet another drop from $24 to $7, while Goldman kept a Sell rating on MCRB stock.

The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.09, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 1.16.

MCRB Stock Performance Analysis:

Seres Therapeutics Inc [MCRB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.62. With this latest performance, MCRB shares dropped by -0.87% in over the last four-week period, additionally sinking by -67.71% over the last 6 months – not to mention a drop of -77.15% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 51.58, with the RSI for the last a single of trading hit 56.00, and the three-weeks RSI is set at 49.38 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 1.1884, while it was recorded at 1.0840 for the last single week of trading, and 2.7537 for the last 200 days.

Insight into Seres Therapeutics Inc Fundamentals:

Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.47 and a Current Ratio set at 2.71.


With the latest financial reports released by the company, Seres Therapeutics Inc posted -0.54/share EPS, while the average EPS was predicted by analysts to be reported at -0.46/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MCRB.

Seres Therapeutics Inc [MCRB] Institutonal Ownership Details

The top three institutional holders of MCRB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in MCRB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in MCRB stock with ownership which is approximately 5.8325%.